Completed PHASE2 INTERVENTIONAL 2-arm NCT00321932

Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant

A Randomized Phase II of Zoledronic Acid (Zometa) in the Prevention of Osteoporosis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Sponsor: University of Minnesota

Conditions Leukemia Lymphoma Myelodysplastic Syndromes Osteoporosis Ovarian Cancer

Interventions calcium cholecalciferol zoledronic acid

Updated 7 times since 2017 Last updated: Jan 26, 2017 Started: Jul 31, 2005 Primary completion: Mar 31, 2011 Completion: Mar 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00321932, this PHASE2 trial focuses on Leukemia and Lymphoma and remains completed. Sponsored by University of Minnesota, it has been updated 7 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Nov 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Nov 2019 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Minnesota

Data source: University of Minnesota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madison, United States
• Minneapolis, United States